# A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules

> **NCT04567524** · PHASE2 · COMPLETED · sponsor: **Lyndra Inc.** · enrollment: 34 (actual)

## Conditions studied

- Schizophrenia Schizoaffective

## Interventions

- **DRUG:** LYN-005

## Key facts

- **NCT ID:** NCT04567524
- **Lead sponsor:** Lyndra Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-13
- **Primary completion:** 2020-12-22
- **Final completion:** 2020-12-22
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04567524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04567524, "A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04567524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*